Additionally, evaluation of the effectiveness of cell therapy with reprogrammed CD8+ T blood lymphocytes on CSCs obtained from the blood of a patient with SCLC was carried out in vitro. The gene discussed is CD8A; the disease is small cell lung carcinoma.